Repligen (NASDAQ:RGEN) updated its FY 2021 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 2.210-2.280 for the period, compared to the Thomson Reuters consensus estimate of $1.910. The company issued revenue guidance of $565 million-$590 million, compared to the consensus revenue estimate of $513.38 million.Repligen also updated its FY21 guidance to $2.21-2.28 EPS.
Several analysts recently issued reports on the company. Zacks Investment Research cut Repligen from a strong-buy rating to a hold rating and set a $200.00 target price on the stock. in a research note on Tuesday, January 5th. Craig Hallum lifted their price objective on Repligen from $245.00 to $251.00 and gave the stock a buy rating in a research report on Thursday, February 25th. HC Wainwright restated a buy rating and set a $225.00 target price (up previously from $168.00) on shares of Repligen in a report on Monday, April 19th. Finally, SVB Leerink lifted their price target on shares of Repligen from $220.00 to $250.00 and gave the company an outperform rating in a report on Wednesday, March 3rd. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. Repligen currently has an average rating of Buy and an average target price of $215.20.
Shares of NASDAQ:RGEN traded down $13.44 during midday trading on Tuesday, reaching $194.67. The company’s stock had a trading volume of 572,290 shares, compared to its average volume of 383,206. The company has a quick ratio of 12.13, a current ratio of 13.67 and a debt-to-equity ratio of 0.21. The firm has a 50 day moving average of $204.63 and a 200-day moving average of $198.93. The firm has a market capitalization of $10.69 billion, a P/E ratio of 237.40, a PEG ratio of 4.18 and a beta of 0.94. Repligen has a 12-month low of $109.38 and a 12-month high of $228.84.
In other news, CEO Anthony Hunt sold 21,900 shares of the company’s stock in a transaction on Thursday, March 4th. The stock was sold at an average price of $190.19, for a total transaction of $4,165,161.00. Following the transaction, the chief executive officer now directly owns 242,970 shares of the company’s stock, valued at $46,210,464.30. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP James Bylund sold 360 shares of the stock in a transaction on Tuesday, April 6th. The shares were sold at an average price of $204.25, for a total value of $73,530.00. Following the sale, the senior vice president now directly owns 6,324 shares in the company, valued at $1,291,677. The disclosure for this sale can be found here. Insiders have sold a total of 47,382 shares of company stock worth $9,056,388 over the last three months. 1.70% of the stock is currently owned by insiders.
Repligen Corp. provides bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. It serves through the following product lines: Chromatography, Filtration and OEM Products (Proteins). The Chromatography product line includes a number of products used in the downstream purification and quality control of biological drugs.
Read More: What are earnings reports?
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.